In my previous article , I argued that Moderna stock was undervalued. Since then, Moderna's stock has rallied to $170 per share (May 24), surpassing my fair valuation level of $157. However, the stock has since suffered a sell-off, and after the R&D day, the stock price was as I am the head of research for the pre-IPO and venture division of the investment bank. Prior to that, I have been working as a global equity research analyst in an investment bank for the past 5 years. My specialization are Biotechnol ...